Good morning, everyone, and how are you today? The middle of the week is here, which means your survival skills are intact — so far. To celebrate, and to stay on track, you may want to reach for a cup of stimulation. We have already enjoyed a mug of golden French toast, for those interested in a little experimentation. Now, though, the time has come to get busy. So here are a few items of interest to get you started. So dig in and have a smashing day. And one other thing — do keep us in mind if you run across anything intriguing. As always, we accept confidential stuff and enjoy hearing secrets …

Pfizer (PFE) plans to invest $600 million in its venture capital fund, and 25 percent of the funds are being earmarked for research on neuroscience. The move comes six months after the drug maker disclosed it would abandon research into finding new drugs aimed at treating Alzheimer’s and Parkinson’s diseases. The bulk of the funds — $450 million — will be devoted to oncology, inflammation and immunology, rare disease, internal medicine, and vaccines. The new funding will bring total assets managed by Pfizer Ventures to over $1 billion.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy